This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1492 entries already.
Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB.
Novartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has therefore issued a cautious outlook for 2026. The CEO’s high, bonus-driven remuneration has sparked debate.
Leyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies.
Pentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal of Nuclear Medicine confirm the potential of Pentixafor PET/CT as a non-invasive alternative to adrenal venous sampling (AVS) for the subtyping of primary aldosteronism.
PharosAI, a U.K. cancer research consortium bringing together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and Barts Health NHS Trust, has partnered with 10x Genomics to generate large-scale multimodal cancer datasets from archived NHS tumor samples using 10x’s Xenium spatial biology platform.
Swedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases.
French biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent the past year under financial pressure, received approval from the Commercial Court of Lyon last week to restructure its debt and continue operations.
The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant exchange rates to around EUR 3.54 billion, while the operating EBITDA margin rose by 1.7 percentage points to 29.7%.
Newly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.
French biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. The deal strengthens Ipsen’s early-stage neuroscience pipeline while giving Origami a potential path toward global development and commercialization